Cargando…
Precise targeting of POLR2A as a therapeutic strategy for human triple negative breast cancer
TP53 is the most frequently mutated or deleted gene in triple negative breast cancer (TNBC). Both the loss of TP53 and the lack of targeted therapy are significantly correlated with poor clinical outcomes, making TNBC the only type of breast cancer that has no approved targeted therapies. Through in...
Autores principales: | Xu, Jiangsheng, Liu, Yunhua, Li, Yujing, Wang, Hai, Stewart, Samantha, Van der Jeught, Kevin, Agarwal, Pranay, Zhang, Yuntian, Liu, Sheng, Zhao, Gang, Wan, Jun, Lu, Xiongbin, He, Xiaoming |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6449187/ https://www.ncbi.nlm.nih.gov/pubmed/30804480 http://dx.doi.org/10.1038/s41565-019-0381-6 |
Ejemplares similares
-
Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+ breast cancer
por: Liu, Yunhua, et al.
Publicado: (2018) -
A biomimetic hybrid nanoplatform for encapsulation and precisely controlled delivery of therasnostic agents
por: Wang, Hai, et al.
Publicado: (2015) -
Erratum: A biomimetic hybrid nanoplatform for encapsulation and precisely controlled delivery of theranostic agents
por: Wang, Hai, et al.
Publicado: (2016) -
Craniofacial features of POLR3-related leukodystrophy caused by biallelic variants in POLR3A, POLR3B and POLR1C
por: Mirchi, Amytice, et al.
Publicado: (2023) -
Carbon nano-onion-mediated dual targeting of P-selectin and P-glycoprotein to overcome cancer drug resistance
por: Wang, Hai, et al.
Publicado: (2021)